Overview
For people suffering from Type 2 diabetes, stem cell therapy can offer a respite from the symptoms of the disease. Although stem cell therapy cannot cure it, receiving stem cell therapy for diabetes Type 2 from TruStem Cell Therapy has the potential to improve a patients quality of life significantly by reducing symptoms and complications related to Type 2 diabetes, as well as slowing its progression.
For patients receiving stem cell diabetes treatment, it is possible to see improvements in any one or multiple disease-related complications such as stabilization of blood sugar levels, lower blood sugar levels, frequent urination, fatigue, poor wound healing, etc.
TruStem Cell Therapy provides access to diabetes treatment that utilizes a patients stem cells isolated from his or her own fat tissue. There are multiple benefits afforded by the utilization of adipose-derived stem cells, including their ability to differentiate into a broad variety of cell types (neurons, bone, cartilage, muscle, tendon, etc.), they are present at comparatively much higher levels than other stem cell types; possess higher immunomodulatory capacity; and they do not endanger a patients health the way other stem cells might.
There are three steps to the treatment process:
Approximately 150 to 250 ccs of a patients own fat tissue is harvested through a minimally invasive procedure. Generally, this fat tissue is collected from around the patients belly region.
Typically, patients will experience some soreness and bruising lasting roughly a week as a result of the harvesting procedure. Additional complications from stem cell therapy for diabetes have not been observed. Although the FDA has not approved stem cell therapy for diabetes Type 2 as of yet, more than 100 studies and clinical trials have demonstrated the safety and minimal side effect profile of stem cell therapy.
Because every patient responds differently to treatment, it is difficult to predict the timeline of a patients response. It could take weeks to months for stem cell therapy for diabetes Type 2 to provide noticeable results.
Our focus is on safety, efficacy and patient-centric care when providing access to superior stem cell therapy. We utilize only board-certified surgeons, physicians and accredited clinicians to provide care for patients. Our laboratory protocols are developed and refined by our PhD neuroscientist, and our clinical team has extensive expertise in practicing cellular-based medicine. Our accredited surgical centers are geared toward enhanced procedural and patient safety. Above all, TruStem Cell Therapy has skilled patient advocates who are trained to provide truthful, realistic expectations resulting from stem cell therapy. We do not make outlandish promises of cures, or inaccurate claims related to improvement rates.
Type 2 diabetes is a relatively common disorder that causes high blood sugar levels. Though it may sound innocuous, high blood sugar can lead to symptoms like frequent urination, increased thirst and blurred vision; as well as more severe health-related complications, including fatigue, cardiovascular disease, stroke and kidney failure.
Type 2 diabetes develops when the body becomes resistant to or stops producing insulin: a hormone that helps remove sugar from blood and allows it to be absorbed into various tissue types like muscle and fat. Exactly why this happens is unknown, although genetics and environmental factors such as excess weight and inactivity seem to be contributing factors.
Living with Type 2 diabetes can be difficult, but TruStem Cell Therapy may be able to help you live a more comfortable and fulfilling life through stem cell diabetes treatment. If youd like to learn more about how we might be able to help you, contact us today.
Symptoms/Complications
Frequent urination
Increased thirst and hunger
Blurred vision
Fatigue
Cardiovascular disease
Stroke
Blindness
Kidney failure
Lower limb amputations
Causes
Type 2 diabetes develops when the body becomes resistant to insulin or when the pancreas stops producing enough insulin. Exactly why this happens is unknown, although genetics and environmental factors, such as excess weight and inactivity, seem to be contributing factors.
TruStem Cell Therapy
TruStem Cell Therapy provides access to treatment that utilizes a patients stem cells isolated from their own fat tissue. There are multiple inherent benefits afforded by the utilization of adipose derived stem cells including their ability to differentiate into a broad variety of cells types (neurons, bone, cartilage, muscle, tendon, etc.), they are present at comparatively much higher levels than other stem cell types, possess higher immunomodulatory capacity, and they do not endanger a patients health the way other stem cells might.
Approximately 150-250ccs of a patients own fat tissue is harvested through a minimally invasive, mini liposuction procedure. Generally, this fat tissue is collected from around the patients belly region.
Harvested fat tissue is immediately taken to the onsite laboratory for processing. At this step, an optimized protocol is used to isolate the maximum number of stem cells from collected fat tissue.
TruStem Cell Therapy utilizes both systematic and novel administration methods to fully saturate the body with stem cells while targeting specific areas of injury.
DT2 patients who receive stem cell therapy through us can receive multiple systemic and targeted administration methods:
Intravenously ADSCs are delivered via a vein for distribution throughout the body
Direct site injections ADSCs are delivered to sites that need repair, such asIschemic limbs andNeuropathy or nerve damage to various areas of the body.
Our focus is safety, efficacy, and patient-centric care when providing access to superior stem cell therapy.
We utilize only board certified surgeons, physicians and accredited clinicians to provide care for patients.
Laboratory protocols are developed and refined by our PhD Neuroscientist.
A clinical team with expertise in practicing cellular based medicine.
Accredited Surgical Centers for enhanced procedural and patient safety
Targeted administration methods that direct stem cells toward specific
Skilled Patient Advocates who are trained to provide truthful, realistic expectations resulting from stem cell therapy. We do not make outlandish promises of cures or inaccurate claims related to improvement rates.
FAQ
Unfortunately, not at this time. We are only providing access to stem cell therapy for Type 2 Diabetes. To date there is not enough research or clinical evidence to support the use of adult stem cell therapy as an effective therapy option for patients with type 1 diabetes. However, this may change with future advances so please return for updates on this matter.
It is important for patients and caregivers to understand that current therapies, including stem cell treatment, does not provide a cure for type 2 diabetes. However, TruStem Cell Therapy does have the potential to improve a patients quality of life by reducing symptoms and complications related to type 2 diabetes as well as slowing its progression.
The FDA has not approved stem cell therapy for type 2 diabetes. As noted above, studies have demonstrated the safety and efficacy of stem cell therapy for this condition but additional studies are needed before FDA approval can be secured.
It is possible through these treatments, to improve a patients quality of lifebyminimizing disease relatedsymptoms and complications. For Type II Diabetes patients, it is possible to see improvements in any one ormultipledisease related complications such as: stabilization of blood sugar levels, lower blood sugar levels, frequent urination, fatigue, poor wound healing, etc If you have questions regarding how these treatments may help you, please contact one of our Patient Advocates to learn more.
It is difficult to predict the timeline of a patients response. Every patient responds differently to treatment. It could take weeks to months for the stem cells to provide noticeable results.
Typically patients will experience some level of soreness and bruising lasting roughly a week as a result of the mini-liposuction procedure. Additional complications have not been observed. Over a hundred studies and clinical trials have demonstrated the safety and minimal side-effect profile of stem cell therapy.
Read the rest here:
Stem Cell Treatment & Therapy for Diabetes Type 2 in ...
- UC Irvine Study Reveals Risks Associated with Direct-to-Consumer Ads for Stem Cell and Exosome COVID-19 Therapies - India Education Diary - November 18th, 2023
- STEM | Description, Development, & Facts | Britannica - January 31st, 2023
- What is STEM Education? | Live Science - January 31st, 2023
- Science, Technology, Engineering, and Math, including Computer Science - ed - January 23rd, 2023
- What Does STEM Stand For? Definition, Degrees and More - January 23rd, 2023
- What Is STEM? - Definition & Resources for Teachers - January 23rd, 2023
- Science, technology, engineering, and mathematics - Wikipedia - January 23rd, 2023
- Stem Definition & Meaning - Merriam-Webster - January 23rd, 2023
- November: labblood-study | News and features - University of Bristol - November 7th, 2022
- Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem, a Novel Cell Therapy for the... - November 7th, 2022
- Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and... - November 7th, 2022
- Type 2 Diabetes Stem Cell Therapy - Top U.S. Stem Cell ... - January 1st, 2022
- Cancer Drug Approvals from 2021 That Patients May Have Missed - Curetoday.com - January 1st, 2022
- Late effects in survivors of high-risk neuroblastoma following stem cell transplant with and without total body irradiation - DocWire News - January 1st, 2022
- The new life of a teenager with a strange tumor on his face after the operation - Market Research Telecast - January 1st, 2022
- Best of what was new in diabetes health for 2021 - Dickson Post - January 1st, 2022
- Hematopoietic Stem Cell Transplantation - StatPearls ... - December 22nd, 2021
- Autologous Stem Cell Transplant for Multiple Myeloma - December 22nd, 2021
- City of Hope presents leading-edge research on blood cancer therapies and its vaccine to reduce stem cell transplant complications at American Society... - December 22nd, 2021
- Adaptation Is Key to Advancing Care for Adult Patients With Leukemia - OncLive - December 22nd, 2021
- FDA Approves First Drug to Prevent Graft Versus Host Disease | FDA - FDA.gov - December 22nd, 2021
- Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients - Yahoo Finance - December 22nd, 2021
- After throwing goodbye party, woman with cancer finds hope close to home in Austin - Austin American-Statesman - December 22nd, 2021
- Dr. K.M. Cherian Heart Foundation & Educational Society Organized Cme Programme & Workshop On Cell Culture And Regenerative Medicine - APN... - December 22nd, 2021
- Namesake of new center a young man in love with the pursuit of knowledge - The Saint Anselm Crier - November 7th, 2021
- Red Cross blood drive focuses on sickle cell disease fight - Palladium-Item - November 7th, 2021
- Shockwave therapy brings new healing opportunities for heart attack patients and hope for people with spinal cord injuries - KULR-TV - November 7th, 2021
- 1st CRISPR Gene Editing Trial Slated to Open in Severe SCD Patients - Sickle Cell Anemia News - April 4th, 2021
- Transplant After CD19 CAR T-Cell Therapy Shows Durable Disease Control in Children, Young Adults With B-ALL - Cancer Network - April 4th, 2021
- Timely Bone Marrow Transplant by Fortis gives new lease of life to a patient with Multiple Myeloma - APN News - April 4th, 2021
- Kirron Kher is suffering with Multiple Myeloma: Know the causes, symptoms and more about this type of blood cancer - Jagran English - April 4th, 2021
- Decitabine Improved Outcomes for Patients With Refractory Prolonged Isolated Thrombocytopenia - Hematology Advisor - April 4th, 2021
- Lake in the Hills police officer and father of 4 kids battling rare cancer forced to retire - Lake and McHenry County Scanner - April 4th, 2021
- Insulin 100: How the road to a diabetes cure is yielding better treatments - News@UofT - April 4th, 2021
- Boxcar Scars Market |Exclusive Report on Latest Trends and Market Growth Opportunities - BioSpace - April 4th, 2021
- Merck Receives Positive EU CHMP Opinion for Updated Label of KEYTRUDA (pembrolizumab) To Include Results of Phase 3 KEYNOTE-361 Trial in Certain Adult... - April 4th, 2021
- BeyondSpring Announces Submission of New Drug Application to US FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of... - April 4th, 2021
- Types of leukemia: Prevalence, treatment options, and prognosis - Medical News Today - February 14th, 2021
- Roche receives first FDA clearance for urine sample type for BK virus quantitative test to aid in the improvement of care for transplant patients -... - February 14th, 2021
- Energy drinks may damage the heart, researchers warnshould the FDA get involved? - Cardiovascular Business - February 14th, 2021
- FDA Approves G1 Therapeutics' COSELA (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced... - February 14th, 2021
- Easter Ross mum of blood cancer tot urges would-be stem cell donors to show the love this Valentine's Day; Alness lass Adeline Davidson's plight... - February 14th, 2021
- Global Induced Pluripotent Market Positive Outlook, Revenue Generation & Leading Manufacturers, Forecast 2026||CELGENE CORPORATION; Astellas... - February 14th, 2021
- Leukemia in children: Symptoms, causes, treatment, outlook, and more - Medical News Today - February 7th, 2021
- After Bone Marrow Donation Saves 9-Year-Old Boy With Cancer, Boston Mom Fights To Raise Awareness - Here And Now - February 7th, 2021
- Understanding bone marrow transplant: The guidelines and the protocols - The New Indian Express - February 4th, 2021
- Why Cynata is hopeful its COVID treatment trial will succeed where others have failed - Business News Australia - February 4th, 2021
- Mobilize family caregivers to speed the rollout of Covid-19 vaccines - STAT - February 4th, 2021
- People With Cancer Should Receive COVID-19 Vaccine, Experts Say - Cancer Health Treatment News - February 4th, 2021
- Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy f - PharmiWeb.com - February 4th, 2021
- APOE Tied to Increased Susceptibility to SARS-CoV-2 | ALZFORUM - Alzforum - February 4th, 2021
- Transforming Outcomes in Advanced CSCC with Immunotherapy - LWW Journals - February 4th, 2021
- Ashley Cain is living his worst nightmare as his baby daughter battles leukaemia in hospital - The Sun - February 4th, 2021
- Canada's blood supply has a diversity problem and people are dying because of it - CBC.ca - February 1st, 2021
- Autologous Stem Cell and Non Stem Based therapies Market Share, Size 2021 Global Industry Future Trends, Growth, Strategies,, Segmentation, In-depth... - February 1st, 2021
- Merck Receives Positive EU CHMP Opinion for Expanded Approval of KEYTRUDA (pembrolizumab) in Certain Patients With Relapsed or Refractory Classical... - February 1st, 2021
- Merck Presents Results From Head-to-Head Phase 3 KEYNOTE-598 Trial Evaluating KEYTRUDA (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA... - February 1st, 2021
- Disabled People Are Waiting, Anxiously, For Lifesaving Covid-19 Vaccinations - Forbes - February 1st, 2021
- Family of Belfast woman Eimear Gooderham (25) share memories and dealing with grief in special UTV programme - Belfast Telegraph - February 1st, 2021
- Single-cell molecular profiling of all three components of the HPA axis reveals adrenal ABCB1 as a regulator of stress adaptation - Science Advances - February 1st, 2021
- The Need for New Biological Targets for Therapeutic Intervention in COPD - Pulmonology Advisor - February 1st, 2021
- What Patients With Cancer, Survivors Need to Know About the Emergency Use Authorization of COVID-19 Vaccine - Curetoday.com - December 19th, 2020
- Every Patient Treated With CRISPR Gene Therapy for Blood Diseases Continues to Thrive, More Than a Year On - Good News Network - December 19th, 2020
- Are Hiccups a Sign of the New Coronavirus? - Healthline - December 19th, 2020
- KEYTRUDA Plus LENVIMA Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective... - December 19th, 2020
- Covid-19 can have impact on heart too, say experts - Hindustan Times - December 19th, 2020
- Even if You've Had COVID-19 You Still Need the Vaccine - Healthline - December 19th, 2020
- The Link Between Cancer and Metabolic Dysfunction - Technology Networks - December 19th, 2020
- Diamyd Medical and Critical Path Institute announce data sharing collaboration to develop advanced drug development tools in type 1 diabetes -... - December 19th, 2020
- Gene therapy gives man with sickle cell disease the chance for a better future - Science Codex - December 3rd, 2020
- Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety and Therapeutic Efficacy of Angiogenesis Induced by Intraarterial Autologous... - December 3rd, 2020
- Coronavirus Updates: The Latest Treatments and Vaccines - GovTech - December 3rd, 2020
- Graft Versus Host Disease (GVHD) Patient Population, Treatment Algorithm, Medical Practices And Epidemiology Forecast To 2030 - The Market Feed - December 3rd, 2020
- Government of Canada and JDRF Canada announce new research funding to accelerate stem cell-based therapies for type 1 diabetes - India Education Diary - December 3rd, 2020
- Coinfection: more than the sum of its parts - Science Codex - November 19th, 2020
- Angiocrine Bioscience Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to AB-205 (Universal E-CEL Cell Therapy) to... - November 17th, 2020
- FDA Approves Merck's KEYTRUDA in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple?Negative Breast... - November 17th, 2020
- Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection - DocWire News - November 17th, 2020
- Cleveland Clinic team draws a link between COVID-19 protection and the sleep aid melatonin - FierceBiotech - November 17th, 2020
- UH announces participation in clinical trial testing antibodies to treat COVID-19 in adults - News 5 Cleveland - November 7th, 2020